August 31, 2022
Daiichi Sankyo said on August 30 that it has submitted an application seeking approval for its FLT3 inhibitor Vanflyta (quizartinib) for the first-line treatment of FLT3-ITD positive acute myeloid leukemia (AML). The submission is based on data from the global...read more